Exicure

Exicure Tax Rate

The Effective Tax Rate of Exicure (XCUR) as of Nov 17, 2026 is 11.36 %. In the previous year, Effective Tax Rate was -0.08 % — a change of -13,866.49% (higher).

Tax Rate

11.36 %

YoY

-13,866.49%

Last updated:

Effective Tax Rate of Exicure is 2025 11.36 % . Effective Tax Rate of Exicure was 2024 -0.08 % . It decreases by -13,866.49% higher compared to the previous year.

The Exicure Tax Rate history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Rate
Date
Tax Rate
Jan 1, 2018
-1.89 USD
Jan 1, 2019
-4.43 USD
Jan 1, 2020
-3.63 USD
Jan 1, 2021
-2.62 USD
Jan 1, 2022
-8.81 USD
Jan 1, 2023
100.00 USD
Jan 1, 2024
-0.08 USD
Jan 1, 2025
11.36 USD
The Exicure Tax Rate history
YEARTax RateYoY
11.36 %-13,866.49%
-0.08 %-100.08%
100.00 %-1,235.41%
-8.81 %+236.06%
-2.62 %-27.76%
-3.63 %-18.08%
-4.43 %+134.68%
-1.89 %-78.92%
-8.95 %+126.76%
-3.95 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exicure Stock analysis

What does Exicure do? Exicure, Inc. generates revenue through the development and commercialization of therapeutic products based on its Spherical Nucleic Acid (SNA) technology. The company focuses on immuno-oncology, genetic disorders, and other indications, with a pipeline including AST-008, XCUR-FXN, and XCUR17. AST-008 is a toll-like receptor 9 agonist designed to activate the innate immune system and induce anti-cancer responses, particularly when combined with checkpoint inhibitors. XCUR-FXN targets Friedreich’s ataxia (FA) in preclinical development, while XCUR17 is an SNA targeting IL-17RA mRNA for inflammatory disorders, Netherton syndrome, and hair loss disorders. The primary buyers of Exicure's products are pharmaceutical companies and healthcare providers seeking innovative treatments for complex conditions. The company's SNA technology enables therapeutic oligonucleotides to work across various cells and tissues, addressing unmet medical needs in immuno-oncology and genetic disorders. Commercial partnerships and licensing agreements are likely key revenue streams, though specific partners are not named in the business description. Exicure's product segments include immuno-oncology (AST-008), genetic disorders (XCUR-FXN), and inflammatory conditions (XCUR17). These segments target patients with specific diseases, such as cancer, Friedreich’s ataxia, and inflammatory disorders, where current treatments are limited. The company's focus on SNA technology differentiates its approach, aiming to unlock new therapeutic possibilities in these areas. Exicure is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exicure stock

Effective Tax Rate of Exicure is 11.36 % in 2025.

Effective Tax Rate of Exicure changed from -0.08 % to 11.36 %, representing a -13,866.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Effective Tax Rate Exicure since 2006 – with annual values, charts, and detailed analysis.

The effective tax rate measures the actual percentage of pretax income paid in taxes. It reflects the company's tax efficiency and planning.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Effective Tax Rate's Exicure with sector peers and the industry average to assess whether it is attractive.

To evaluate Effective Tax Rate's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Effective Tax Rate.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Exicure

All Key Metrics — Exicure